{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:15Z","timestamp":1789056435009,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201830","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:27:48Z","timestamp":1785770868000},"page":"201830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["AAVR disruption as a producer-cell engineering strategy for enhanced supernatant-based recovery of selected AAV serotypes"],"prefix":"10.1016","volume":"34","author":[{"given":"Kenji","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1783-4222","authenticated-orcid":false,"given":"Yuji","family":"Tsunekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naymel A.","family":"Guzman Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201830_bib1","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1128\/jvi.68.9.5656-5666.1994","article-title":"Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors","volume":"68","author":"Podsakoff","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201830_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1743-422X-10-74","article-title":"A survey of ex vivo\/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype","volume":"10","author":"Ellis","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.omta.2026.201830_bib3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1089\/hum.2010.107","article-title":"Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing","volume":"21","author":"Vandenberghe","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201830_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.1068","article-title":"Purification of Adeno-Associated Viral Vector Serotype 9 Using Ceramic Hydroxyapatite Chromatography and its Analysis","volume":"4","author":"Kurosawa","year":"2024","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.omta.2026.201830_bib5","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/bit.28524","article-title":"Development of a novel purification method for AAV vectors using tangential flow filtration","volume":"120","author":"Miyaoka","year":"2023","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.omta.2026.201830_bib6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41434-023-00398-x","article-title":"Large-scale purification of functional AAV particles packaging the full genome using short-term ultracentrifugation with a zonal rotor","volume":"30","author":"Wada","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201830_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/bit.70090","article-title":"Downstream Process Intensification for AAV Purification by Affinity Chromatography Using Single Pass Tangential Flow Filtration","volume":"123","author":"Chaubal","year":"2026","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.omta.2026.201830_bib8","doi-asserted-by":"crossref","first-page":"22657","DOI":"10.1021\/acsomega.4c10900","article-title":"Improving AAV Production Yield and Quality for Different Serotypes Using Distinct Processing Methods","volume":"10","author":"Khaparde","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.omta.2026.201830_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2020.108914","article-title":"Efficient whole brain transduction by systemic infusion of minimally purified AAV-PHP.eB","volume":"346","author":"Konno","year":"2020","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.omta.2026.201830_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature16465","article-title":"An essential receptor for adeno-associated virus infection","volume":"530","author":"Pillay","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201830_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omtm.2018.10.015","article-title":"Highly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9","volume":"11","author":"Tomono","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201830_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02213-17","article-title":"An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor","volume":"92","author":"Dudek","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201830_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","article-title":"Adeno-associated virus (AAV) cell entry: structural insights","volume":"30","author":"Meyer","year":"2022","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.omta.2026.201830_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00391-17","article-title":"Adeno-associated Virus (AAV) Serotypes Have Distinctive Interactions with Domains of the Cellular AAV Receptor","volume":"91","author":"Pillay","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201830_bib15","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41467-021-21935-5","article-title":"Adeno-associated virus capsid assembly is divergent and stochastic","volume":"12","author":"W\u00f6rner","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201830_bib16","doi-asserted-by":"crossref","first-page":"11072","DOI":"10.1128\/JVI.77.20.11072-11081.2003","article-title":"Identification of a heparin-binding motif on adeno-associated virus type 2 capsids","volume":"77","author":"Kern","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201830_bib17","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1016\/j.cell.2025.06.026","article-title":"An alternate receptor for adeno-associated viruses","volume":"188","author":"Dhungel","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201830_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01330-23","article-title":"Identification of host essential factors for recombinant AAV transduction of the polarized human airway epithelium","volume":"97","author":"Hao","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201830_bib19","article-title":"CRISPR screen reveals modifiers of rAAV production including known rAAV infection genes playing an unexpected role in vector production","volume":"33","author":"O'Driscoll","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201830_bib20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/bioinformatics\/btu743","article-title":"CRISPRdirect: software for designing CRISPR\/Cas guide RNA with reduced off-target sites","volume":"31","author":"Naito","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omta.2026.201830_bib21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201830_bib22","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1242\/dev.136325","article-title":"Developing a de novo targeted knock-in method based on in utero electroporation into the mammalian brain","volume":"143","author":"Tsunekawa","year":"2016","journal-title":"Development"},{"key":"10.1016\/j.omta.2026.201830_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101157","article-title":"Engineering a highly durable adeno-associated virus receptor for analytical applications","volume":"31","author":"Yoshida","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201830_bib24","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2110","article-title":"Virus Binding and Internalization Assay for Adeno-associated Virus","volume":"7","author":"Berry","year":"2017","journal-title":"Bio. Protoc."},{"key":"10.1016\/j.omta.2026.201830_bib25","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1085","article-title":"Systemic delivery of genes to striated muscles using adeno-associated viral vectors","volume":"10","author":"Gregorevic","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201830_bib26","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1128\/jvi.71.9.6823-6833.1997","article-title":"Cloning of adeno-associated virus type 4 (aav4) and generation of recombinant aav4 particles","volume":"71","author":"Chiorini","year":"1997","journal-title":"J. Virol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:17:04Z","timestamp":1789053424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001655"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201830","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAVR disruption as a producer-cell engineering strategy for enhanced supernatant-based recovery of selected AAV serotypes","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201830"}}